Targeting LTBP2 Reveals a Novel Anti-Cardiac Remodeling Mechanism of Finerenone Against Doxorubicin-Induced Cardiotoxicity
Biomolecules · 05.12.2025 · 15 (12) · 1703
DOI: 10.3390/biom15121703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 05.12.2025. Verfasst von Heng Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China. Hauptthemen laut MEDLINE: Doxorubicin, Cardiotoxicity, Latent TGF-beta Binding Proteins, Naphthyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research & Development plan of Hubei Province, Research and Development Program of Hubei Province.
Abstract (Originalsprache)
Despite the clinical efficacy of doxorubicin (DOX), effective strategies to prevent its cardiotoxicity are still lacking. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), has demonstrated cardioprotective properties; however, its role and mechanism in DOX-induced cardiotoxicity (DIC) remain unclear. In this study, Finerenone treatment was found to significantly alleviate DOX-induced cardiac dysfunction and pathological remodeling in both mouse models and cultured cells. Mechanistically, molecular docking suggests that Finerenone may directly bind to Latent Transforming Growth Factor Beta Binding Protein 2 (LTBP2), a key regulator of TGF-β bioavailability. This potential binding could inhibit the LTBP2–TGF-β axis, thereby suppressing DOX-induced activation and subsequent Smad3 phosphorylation. The importance of this pathway was supported by the similar anti-fibrotic effects observed with the TGF-β inhibitor LY2109761. However, our findings on the direct binding of Finerenone to LTBP2 are preliminary and require further validation through additional experimental approaches. These results identify LTBP2 as a novel direct target of Finerenone and reveal an additional mechanism underlying its cardioprotective action, suggesting its potential repurposing for the prevention of DIC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan 430060, China.
- Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China.
ORCID-Profile: Heng Zhang, Bo Shen
Förderung
- National Natural Science Foundation of China
- Research & Development plan of Hubei Province
- Research and Development Program of Hubei Province
Zitieren
APA
Zhang, H., Zhao, N., Xie, S., Li, L., Zeng, X., Wang, S., Yan, L., Shen, B., & Deng, W. (2025). Targeting LTBP2 Reveals a Novel Anti-Cardiac Remodeling Mechanism of Finerenone Against Doxorubicin-Induced Cardiotoxicity. Biomolecules, 15(12), 1703. https://doi.org/10.3390/biom15121703
Vancouver
Zhang H, Zhao N, Xie S, Li L, Zeng X, Wang S, et al. Targeting LTBP2 Reveals a Novel Anti-Cardiac Remodeling Mechanism of Finerenone Against Doxorubicin-Induced Cardiotoxicity. Biomolecules. 2025;15(12):1703. doi:10.3390/biom15121703
BibTeX
@article{Zhang2025,
author = {Zhang, Heng and Zhao, Nan and Xie, Saiyang and Li, Lanlan and Zeng, Xiaofeng and Wang, Shasha and Yan, Ling and Shen, Bo and Deng, Wei},
title = {Targeting LTBP2 Reveals a Novel Anti-Cardiac Remodeling Mechanism of Finerenone Against Doxorubicin-Induced Cardiotoxicity},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {12},
pages = {1703},
doi = {10.3390/biom15121703}
}
EUVIMED